Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author(s):
Baumert, B.G.; Hegi, M.E.; Bent, M.J. van den; Deimling, A. von; Gorlia, T.; Hoang-Xuan, K.; Brandes, A.A.; Kantor, G.; Taphoorn, M.J.B.; Hassel, M. ben; Hartmann, C.; Ryan, G.; Capper, D.; Kros, J.M.; Kurscheid, S.; Wick, W.; Enting, R.; Reni, M.; Thiessen, B.; Dhermain, F.; Bromberg, J.E.; Feuvret, L.; Reijneveld, J.C.; Chinot, O.; Gijtenbeek, J.M.M.; Rossiter, J.P.; Dif, N.; Balana, C.; Bravo-Marques, J.; Clement, P.M.; Marosi, C.; Tzuk-Shina, T.; Nordal, R.A.; Rees, J.; Lacombe, D.; Mason, W.P.; Stupp, R.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-11-30
Language
English
Is part of
The Lancet Oncology (2016), Vol. 17, no. 11, p. 1521-1532
hdl
1887/112667
doi
10.1016/S1470-2045(16)30313-8